novo nordisk fda semaglutide Novo's Ozempic wins nod to curb kidney disease risks Novo says it's submitted obesity
Description
Our Website is getting some work done too, more coming soon!
The primary endpoint was total body weight loss percentage (TBWL%) at 12 months
Hanmi expects to initiate Phase 1 clinical trials for HM17321 in the second half of 2025.According to recent reports from GlobalData Patent Analytics and IFI CLAIMS Patent Services, Hanmi ranks among the global leaders in both the volume and quality of obesity drug patent filings, alongside multinational pharmaceutical companies such as Eli Lilly and Novo Nordisk.Innovation in metabolic and endocrine diseases has been a core focus for Hanmi over many years, and the ADA 2025 presentations represent a critical opportunity to showcase our global competitiveness, said Dr
Semaglutide can cause nausea and digestive discomfort, especially during dose escalation
PlexusDx patients combine medication with evidence-based nutrition to maximize results and minimize side effects
